Targeted Therapy Clinical Trials

13 recruiting

Targeted Therapy Trials at a Glance

13 actively recruiting trials for targeted therapy are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Beijing, Chengdu, and Beijing. Lead sponsors running targeted therapy studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, West China Hospital, and M.D. Anderson Cancer Center.

Browse targeted therapy trials by phase

Treatments under study

About Targeted Therapy Clinical Trials

Looking for clinical trials for Targeted Therapy? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Targeted Therapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Targeted Therapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Targeted TherapyIDH1-Mutated MalignanciesMutations
M.D. Anderson Cancer Center68 enrolled1 locationNCT07032727
Recruiting

Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy

Targeted TherapyImmunotherapyHepatocellular Carcinoma (HCC)+2 more
Nanfang Hospital, Southern Medical University90 enrolled1 locationNCT07436845
Recruiting
Phase 1

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

Targeted TherapyExosomeHealthy Subjects
Shine-On Biomedical Co., Ltd.15 enrolled1 locationNCT07219940
Recruiting
Phase 3

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Esophagus CancerChemotherapy EffectTargeted Therapy+3 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled5 locationsNCT04821778
Recruiting
Phase 3

Neoadjuvant Treatment Modalities in Esophageal Cancer

Esophageal CancerSurgeryChemotherapy Effect+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled1 locationNCT04821843
Recruiting
Phase 2

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

Rectal CancerRectal AdenocarcinomaTargeted Therapy+6 more
Ruijin Hospital104 enrolled1 locationNCT07198165
Recruiting
Phase 2

Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer

ChemotherapyTargeted TherapyImmunotherapy+2 more
Sun Yat-sen University57 enrolled1 locationNCT06764680
Recruiting
Phase 1Phase 2

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Neoadjuvant TherapyHNSCCTargeted Therapy+2 more
West China Hospital29 enrolled1 locationNCT07010120
Recruiting
Phase 2

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Targeted TherapyImmunotherapyRadiation Therapy+1 more
Peking University First Hospital30 enrolled1 locationNCT06889649
Recruiting
Phase 1

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

Neoadjuvant TherapyHNSCCTargeted Therapy+2 more
West China Hospital21 enrolled1 locationNCT06741982
Recruiting

Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer

Breast CancerTargeted TherapyHematological Toxicity
Fudan University1,000 enrolled1 locationNCT06503380
Recruiting

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

NSCLCTargeted TherapyEvaluation
Xueqin Yang44 enrolled1 locationNCT06142058
Recruiting
Phase 2

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT05983107